It’s no secret that Dua Lipa maintains a well-toned physique, frequently sharing snippets of her rigorous workout sessions and passion for yoga on Instagram. Observing the Grammy winner’s defined abs, ...

Red was the hue du jour donned by the staff and residents at Essex Center this week as they participated in a jumping jacks competition among Centers Health Care facilities as part of a comprehensive ...

Major stock indexes closed lower on Friday, after the week saw a flurry of corporate earnings reports from major tech firms, including Alphabet and Amazon. The healthcare industry also had its fair ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a landscape of robust demand for its groundbreaking diabetes and obesity ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other large-cap value stocks. The market outlook is as uncertain as it gets. On January 18 ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Lepodisiran sodium is under clinical development by Eli ... s health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.